{"id":"bms-986374","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PRMT5 is an epigenetic enzyme that catalyzes the addition of methyl groups to arginine residues on histone and non-histone proteins, regulating gene expression and protein function. By inhibiting PRMT5, BMS-986374 disrupts methylation-dependent pathways involved in cancer cell survival and proliferation, particularly in tumors with certain genetic dependencies. This mechanism is especially relevant in cancers with MTAP loss or other genetic alterations that create synthetic lethal interactions with PRMT5 inhibition.","oneSentence":"BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:06.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion"},{"name":"Other solid tumors with MTAP loss or PRMT5 dependency"}]},"trialDetails":[{"nctId":"NCT05369832","phase":"PHASE4","title":"An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-16","conditions":"Colitis, Ulcerative","enrollment":139},{"nctId":"NCT06181630","phase":"PHASE4","title":"A Lactation Study in Women Receiving Treatment With Ozanimod","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-15","conditions":"Lactating Women, Breastfed Infants","enrollment":""},{"nctId":"NCT05470985","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-22","conditions":"Crohn Disease","enrollment":5},{"nctId":"NCT06396039","phase":"PHASE4","title":"A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-05-15","conditions":"Relapsing Multiple Sclerosis","enrollment":84},{"nctId":"NCT05644665","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Ulcerative Colitis","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ozanimod"],"phase":"marketed","status":"active","brandName":"BMS-986374","genericName":"BMS-986374","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins. Used for Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion, Other solid tumors with MTAP loss or PRMT5 dependency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}